Bluebird Bio traded at $3.29 this Thursday May 19th, decreasing $0.04 or 1.20 percent since the previous trading session. Looking back, over the last four weeks, Bluebird Bio lost 22.04 percent. Over the last 12 months, its price fell by 88.82 percent. Looking ahead, we forecast Bluebird Bio to be priced at 3.40 by the end of this quarter and at 3.16 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Agios Pharmaceuticals 20.98 -0.18 -0.83% -63.05%
Applied Genetic Technologies 0.79 -0.04 -4.46% -80.73%
Alnylam Pharmaceuticals 128.07 -0.24 -0.19% -5.08%
Amgen 245.03 1.07 0.44% -2.74%
Arrowhead Research 34.44 0.24 0.70% -51.78%
Avrobio Inc 0.77 0.02 2.70% -91.34%
Biogen 193.14 -2.57 -1.31% -32.60%
Bluebird Bio 3.29 -0.04 -1.20% -88.82%
BioMarin Pharmaceutical 79.04 0.86 1.10% 3.43%
Gilead Sciences 63.33 0.11 0.17% -8.68%
Intercept Pharmaceuticals 17.47 -0.41 -2.27% 2.80%
Immunogen 3.42 -0.09 -2.43% -48.02%
Incyte Corp 74.37 0.98 1.34% -10.94%
Ionis Pharmaceuticals 37.95 -0.44 -1.15% 7.32%
Moderna Inc 143.38 5.67 4.12% -13.61%
Mirati Therapeutics 59.49 1.81 3.14% -61.35%
Nektar Therapeutics 3.83 0.03 0.66% -79.28%
Novartis 86.23 -0.77 -0.89% 9.07%
Pfizer 50.67 0.27 0.54% 26.30%
PTC Therapeutics 31.73 0.22 0.70% -16.39%
Ultragenyx Pharmaceutical 46.91 -0.79 -1.66% -56.81%
Regeneron Pharmaceuticals 657.49 -1.72 -0.26% 28.11%
Seattle Genetics 144.35 1.35 0.95% -7.06%
Sangamo BioSciences 3.99 0.22 5.84% -63.53%
Sarepta Therapeutics 69.18 0.71 1.04% -10.06%
Vertex Pharmaceuticals 255.51 3.16 1.25% 17.96%

Indexes Price Day Year
USND 11388 -29.66 -0.26% -15.86%
US2000 1776 1.38 0.08% -19.55%

Bluebird Bio
bluebird bio, Inc. is a biotechnology company. The Company focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. It develops LentiGlobin for sickle cell disease (SCD) as a one-time treatment for patients with SCD, a hereditary blood disorder resulting from a mutation in the ß-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. It builds an integrated product platform with therapeutic in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. Its programs in genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease (SCD); and elivaldogene autotemcel. Its programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.